FDA rebuts criticism of government plan to set ADI of ractopamine

An allegedly proposed acceptable daily intake (ADI) of the leanness-enhancing drug ractopamine, which was criticized by several consumer groups Sunday, is just a consensus reached in a food safety evaluation meeting, Food and Drug Administration (FDA) Director-General Kang Jaw-jou said that day.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)